Benzinga | Nov 16, 2020 06:45AM EST

Morgan Stanley Downgrades Sage Therapeutics to Equal-Weight, Announces $85 Price Target

Morgan Stanley analyst Matthew Harrison downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Equal-Weight and announces $85 price target.